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Scedosporium apiospermum is a soil fungus which may cause severe and often fatal
cerebral mycosis in immunocompetent patients in the case of near drowning and in
immunosuppressed patients such as lung transplant recipients. Due to the low
susceptibility of the fungus to antifungal drugs and to the low permeability of the
blood-brain barrier, it might be difficult to reach a therapeutic tissue concentration.
Indeed, the diffusion of the drug in the brain depends on several parameters such as
integrity of the blood-brain barrier.
To evaluate the drug diffusion, two experimental models were developed in
immunocompetent and immunosuppressed rats. Inocula of S.apiospermum (strain
IHEM 3817): 106 spores in immunocompetent and 105 spores in immunosuppressed
rats were administered in the penile vein and a scale (graded from 0 to 9) was
established based on weight, clinical and neurological signs evaluated by the tail
suspension test. Cerebral involvement was confirmed among others by magnetic
resonance imaging of brain, which  highlighted differences in localisation of fungal
abscesses in brain depending on the immune status. As voriconazole or posaconazole
exhibit an in vitro activity against the tested strain (E-test), they were given to the rats
at doses ranging from 10 to 50 mg/kg/d by i.v. or oral route, respectively (6 rats per
dose and controls). The efficacy criteria was defined as time doubling the survival time
and  absence of  neurological sequelae.
Whatever the immune status, the effective doses were 30 mg/kg/d for voriconazole and
50 mg/kg/d for posaconazole. The chosen doses of voriconazole and posaconazole were
higher than the doses calculated on the basis of data published for mice, rabbits and
guinea pigs.This might be explained by the chosen animal species and  criteria of
efficacy.
So, this infectious model appears to be a valuable tool to evaluate the cerebral
diffusion of two antifungal drugs in rats. The data enable to perform pharmacokinetic
(PK) and pharmacodynamic (PD) studies for PK-PD modelling.
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